The COLCOT study included 4745 patients with myocardial infarction ( within 30 days) and found a reduction in cardiovascular events in those who received colchicine compared with the placebo group.
Colchicine is a potent anti-inflammatory drug, and inflammation is relevant to the progression of atherosclerosis.
In the study all received two antiplatelet agents and a statin, and they underwent angioplasty if necessary. Then they were assigned colchicine at a low dose of 0.5 mg/day or placebo. The average follow-up was 23 months, and the study found a 23% reduction in the primary efficacy outcome, which was the combination of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring revascularization.
In the study the average follow-up was 23 months, so perhaps one should treat these patients for 2 years. COLCOT-T2D will follow patients for 4 years, but for now THE RECOMMENDATION IS at least 2 years of treatment.
Another study presented at AHA was COLCHICINE-PCI, studied patients undergoing angioplasty found that inflammation decreased in the colchicine arm as measured by interleukin-6 levels.
Colchicine in plants
1. Colchicinum or Colchicum: Is a genus of perennial flowering plants containing around 160 species which grow from bulb-like corms. It is a member of the botanical family Colchicaceae. Plants in this genus contain toxic amounts of the alkaloid colchicine which is used pharmaceutically in homeopathy to treat gout and Familial Mediterranean fever.
2. Colchicum Luteum is known by the name of Colchicicum in English, Suranjan in Sanskrit and Hirantutiya in Hindi. The plat version is used in gout in Ayurveda.